Oral Cannabis Did Not Help Chemotherapy-Induced Nerve Pain in a Small Pilot Trial

All 12 participants completed the 8-week trial. Both placebo and cannabis groups improved over time on measures of pain, pain interference, sleep, and well-being. However, cannabis did not improve outcomes beyond placebo, and significantly worsened several endpoints. The study demonstrated that placebo-controlled testing of cannabis capsules is feasible and well-tolerated in this population, but found no signal of efficacy at this dose.

Double-blind, randomized, placebo-controlled pilot study (2019-2021). 12 women with taxane-induced peripheral neuropathy (TIPN) received oral cannabis capsules (100 mg CBD/5 mg THC, TID) or placebo for 8 weeks. Daily questionnaires on pain, sleep, and medication use; weekly neuropathy assessments.

Most breast cancer patients develop taxane-induced neuropathy, and there is no effective treatment. While preclinical studies showed CBD+THC synergistically reduced TIPN, this clinical trial did not replicate that benefit. The strong placebo response highlights why controlled trials are essential for evaluating cannabis as medicine.

The disconnect between promising preclinical data and this negative clinical result is a cautionary tale. It also illustrates why patient testimonials and uncontrolled reports of cannabis for pain are unreliable: the placebo group improved substantially.

Very small pilot sample (N=12). Single fixed dose tested. CBD-dominant formulation may not be optimal. 8-week duration may be insufficient. Both groups requested dose reductions, suggesting tolerability issues even at these relatively low doses.